Cost of surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy

M. Massella, J. Ivanovic, R. Bellagamba, R. De Vita, L. Fracasso, V. Tozzi, V. Fragola, M. Rizzica, P. Narciso

Research output: Contribution to journalArticle

Abstract

This study aims to assess direct cost of reconstructive interventions with facial fillers for treatment of HIV (human immunodeficiency virus)-associated facial lipoatrophy (FLA). Evaluation was performed on data from patients enrolled in one arm of a comparative study of immediate versus delayed reconstructive treatment of facial lipoatrophy. Median costs were standardized for efficacy, estimated using data reported by physicians and patient reported outcomes. The variations of the results were evaluated with a sensitivity analysis. Evaluation was performed on 66 patients characterized by significant differences in terms of severity of FLA. Total cost resulted of €140,416.15, with a median cost per patient of €2126.04 (interquartile range [IQR]: 1599-2822). Taking into consideration severity of disease, median costs were €1641.67 (IQR: 1326.67-2126.04) and 2557.12 (IQR: 1939.34-2872.04) (P = 0.0) respectively for patients with low and high severity scores at baseline. Significant differences in term of cost-effectiveness ratios were also found between patients with different severity of FLA, and sensitivity analysis showed that these ratios increase with higher severity scores at baseline and vary widely depending on the costs of filler. Although these results cannot be considered representative because of important limitations, the present study suggests the severity of disease as an important determinant of costs.

Original languageEnglish
Pages (from-to)223-228
Number of pages6
JournalPatient Preference and Adherence
Volume5
DOIs
Publication statusPublished - 2011

Fingerprint

HIV
Costs and Cost Analysis
costs
Therapeutics
Cost of Illness
Disease
Cost-Benefit Analysis
evaluation
Physicians
physician
determinants

Keywords

  • Antiretroviral therapy
  • Dermal fillers
  • HAART
  • Lipodystrophic syndrome

ASJC Scopus subject areas

  • Social Sciences (miscellaneous)
  • Medicine (miscellaneous)
  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Cost of surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy. / Massella, M.; Ivanovic, J.; Bellagamba, R.; De Vita, R.; Fracasso, L.; Tozzi, V.; Fragola, V.; Rizzica, M.; Narciso, P.

In: Patient Preference and Adherence, Vol. 5, 2011, p. 223-228.

Research output: Contribution to journalArticle

Massella, M. ; Ivanovic, J. ; Bellagamba, R. ; De Vita, R. ; Fracasso, L. ; Tozzi, V. ; Fragola, V. ; Rizzica, M. ; Narciso, P. / Cost of surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy. In: Patient Preference and Adherence. 2011 ; Vol. 5. pp. 223-228.
@article{211e446360d541b4882a9d472fcc8f55,
title = "Cost of surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy",
abstract = "This study aims to assess direct cost of reconstructive interventions with facial fillers for treatment of HIV (human immunodeficiency virus)-associated facial lipoatrophy (FLA). Evaluation was performed on data from patients enrolled in one arm of a comparative study of immediate versus delayed reconstructive treatment of facial lipoatrophy. Median costs were standardized for efficacy, estimated using data reported by physicians and patient reported outcomes. The variations of the results were evaluated with a sensitivity analysis. Evaluation was performed on 66 patients characterized by significant differences in terms of severity of FLA. Total cost resulted of €140,416.15, with a median cost per patient of €2126.04 (interquartile range [IQR]: 1599-2822). Taking into consideration severity of disease, median costs were €1641.67 (IQR: 1326.67-2126.04) and 2557.12 (IQR: 1939.34-2872.04) (P = 0.0) respectively for patients with low and high severity scores at baseline. Significant differences in term of cost-effectiveness ratios were also found between patients with different severity of FLA, and sensitivity analysis showed that these ratios increase with higher severity scores at baseline and vary widely depending on the costs of filler. Although these results cannot be considered representative because of important limitations, the present study suggests the severity of disease as an important determinant of costs.",
keywords = "Antiretroviral therapy, Dermal fillers, HAART, Lipodystrophic syndrome",
author = "M. Massella and J. Ivanovic and R. Bellagamba and {De Vita}, R. and L. Fracasso and V. Tozzi and V. Fragola and M. Rizzica and P. Narciso",
year = "2011",
doi = "10.2147/PPA.S16819",
language = "English",
volume = "5",
pages = "223--228",
journal = "Patient Preference and Adherence",
issn = "1177-889X",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Cost of surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy

AU - Massella, M.

AU - Ivanovic, J.

AU - Bellagamba, R.

AU - De Vita, R.

AU - Fracasso, L.

AU - Tozzi, V.

AU - Fragola, V.

AU - Rizzica, M.

AU - Narciso, P.

PY - 2011

Y1 - 2011

N2 - This study aims to assess direct cost of reconstructive interventions with facial fillers for treatment of HIV (human immunodeficiency virus)-associated facial lipoatrophy (FLA). Evaluation was performed on data from patients enrolled in one arm of a comparative study of immediate versus delayed reconstructive treatment of facial lipoatrophy. Median costs were standardized for efficacy, estimated using data reported by physicians and patient reported outcomes. The variations of the results were evaluated with a sensitivity analysis. Evaluation was performed on 66 patients characterized by significant differences in terms of severity of FLA. Total cost resulted of €140,416.15, with a median cost per patient of €2126.04 (interquartile range [IQR]: 1599-2822). Taking into consideration severity of disease, median costs were €1641.67 (IQR: 1326.67-2126.04) and 2557.12 (IQR: 1939.34-2872.04) (P = 0.0) respectively for patients with low and high severity scores at baseline. Significant differences in term of cost-effectiveness ratios were also found between patients with different severity of FLA, and sensitivity analysis showed that these ratios increase with higher severity scores at baseline and vary widely depending on the costs of filler. Although these results cannot be considered representative because of important limitations, the present study suggests the severity of disease as an important determinant of costs.

AB - This study aims to assess direct cost of reconstructive interventions with facial fillers for treatment of HIV (human immunodeficiency virus)-associated facial lipoatrophy (FLA). Evaluation was performed on data from patients enrolled in one arm of a comparative study of immediate versus delayed reconstructive treatment of facial lipoatrophy. Median costs were standardized for efficacy, estimated using data reported by physicians and patient reported outcomes. The variations of the results were evaluated with a sensitivity analysis. Evaluation was performed on 66 patients characterized by significant differences in terms of severity of FLA. Total cost resulted of €140,416.15, with a median cost per patient of €2126.04 (interquartile range [IQR]: 1599-2822). Taking into consideration severity of disease, median costs were €1641.67 (IQR: 1326.67-2126.04) and 2557.12 (IQR: 1939.34-2872.04) (P = 0.0) respectively for patients with low and high severity scores at baseline. Significant differences in term of cost-effectiveness ratios were also found between patients with different severity of FLA, and sensitivity analysis showed that these ratios increase with higher severity scores at baseline and vary widely depending on the costs of filler. Although these results cannot be considered representative because of important limitations, the present study suggests the severity of disease as an important determinant of costs.

KW - Antiretroviral therapy

KW - Dermal fillers

KW - HAART

KW - Lipodystrophic syndrome

UR - http://www.scopus.com/inward/record.url?scp=84866497638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866497638&partnerID=8YFLogxK

U2 - 10.2147/PPA.S16819

DO - 10.2147/PPA.S16819

M3 - Article

C2 - 21660104

AN - SCOPUS:84866497638

VL - 5

SP - 223

EP - 228

JO - Patient Preference and Adherence

JF - Patient Preference and Adherence

SN - 1177-889X

ER -